Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Prostate Cancer
Interventions
DRUG

ezetimibe 10mg-simvastatin 40mg

Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.

Trial Locations (1)

90048

Cedars Sinai Medical Center, Los Angeles

All Listed Sponsors
collaborator

Roswell Park Cancer Institute

OTHER

lead

Cedars-Sinai Medical Center

OTHER

NCT02534376 - Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal | Biotech Hunter | Biotech Hunter